WHO Embraces Anti-Obesity Jabs in 2025, Sparking Debate

In 2025, the World Health Organization (WHO) significantly shifted its stance on anti-obesity medications by including GLP-1 agonists in its Essential Medicines List for diabetes with obesity and issuing its first guideline for obesity treatment. This move, while conditional and acknowledging cost and access issues, signifies a growing acceptance of these drugs in global public health.

Read the full story on Quick Digest